Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States.

IF 4.7 3区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases and Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-08 DOI:10.1007/s40121-025-01112-7

Mark A Schmidt, Maxim Blum, Judy L Donald, Richard T Meenan, Elvira Carrió, Jan Poolman, Maureen P Neary, Thomas Verstraeten, Jeroen Geurtsen

{"title":"Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States.","authors":"Mark A Schmidt, Maxim Blum, Judy L Donald, Richard T Meenan, Elvira Carrió, Jan Poolman, Maureen P Neary, Thomas Verstraeten, Jeroen Geurtsen","doi":"10.1007/s40121-025-01112-7","DOIUrl":null,"url":null,"abstract":"Introduction: Invasive Escherichia coli disease (IED) incidence has increased over recent years among aging populations and has rising antimicrobial resistance. Here, we report on a comparative, cross-sectional, retrospective analysis of US patients with IED to quantify IED-related healthcare resource utilization (HCRU), costs, and impact on health-related quality of life (HRQoL).Methods: This study included Kaiser Permanente Northwest (KPNW) members aged ≥ 60 years enrolled between July 2019 and January 2020. Patients were divided into three groups: Group 1 had experienced a recent IED episode (≤ 3 weeks before enrollment); Group 2 had experienced a former IED episode (13-18 months before enrollment); Group 3 was at risk with no prior history of IED. Data were collected from electronic hospital records, a patient survey, and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Mean costs were adjusted according to individual follow-up.Results: Patient characteristics were generally consistent across Groups 1 (n = 289), 2 (n = 319), and 3 (n = 340). Inpatient hospitalization was observed in 84%, 44%, and 15% of patients in Groups 1, 2 and 3, respectively. Mean direct costs per patient (per 30-day follow-up) were $17,168, $2530, and $1094 in Groups 1, 2, and 3, respectively. Mean total costs per patient in the year following an IED episode (Group 2) were $35,034 vs. $16,163 in the at-risk Group 3. HRQoL was poor for patients with recent IED, with a mean EQ-5D-5L utility index value of 0.25 on the worst day of illness. During a 12-month follow-up period, rehospitalization rates and mean number of antibiotic prescriptions were ~ threefold higher for patients who recovered from IED vs. those at risk.Conclusions: These data demonstrate substantial short- and long-term impacts of IED on HCRU, IED-related costs, and HRQoL. Additional research is needed to further value the impact of novel IED prevention strategies.","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"569-586"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933493/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-025-01112-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Invasive Escherichia coli disease (IED) incidence has increased over recent years among aging populations and has rising antimicrobial resistance. Here, we report on a comparative, cross-sectional, retrospective analysis of US patients with IED to quantify IED-related healthcare resource utilization (HCRU), costs, and impact on health-related quality of life (HRQoL).

Methods: This study included Kaiser Permanente Northwest (KPNW) members aged ≥ 60 years enrolled between July 2019 and January 2020. Patients were divided into three groups: Group 1 had experienced a recent IED episode (≤ 3 weeks before enrollment); Group 2 had experienced a former IED episode (13-18 months before enrollment); Group 3 was at risk with no prior history of IED. Data were collected from electronic hospital records, a patient survey, and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Mean costs were adjusted according to individual follow-up.

Results: Patient characteristics were generally consistent across Groups 1 (n = 289), 2 (n = 319), and 3 (n = 340). Inpatient hospitalization was observed in 84%, 44%, and 15% of patients in Groups 1, 2 and 3, respectively. Mean direct costs per patient (per 30-day follow-up) were $17,168, $2530, and $1094 in Groups 1, 2, and 3, respectively. Mean total costs per patient in the year following an IED episode (Group 2) were $35,034 vs. $16,163 in the at-risk Group 3. HRQoL was poor for patients with recent IED, with a mean EQ-5D-5L utility index value of 0.25 on the worst day of illness. During a 12-month follow-up period, rehospitalization rates and mean number of antibiotic prescriptions were ~ threefold higher for patients who recovered from IED vs. those at risk.

Conclusions: These data demonstrate substantial short- and long-term impacts of IED on HCRU, IED-related costs, and HRQoL. Additional research is needed to further value the impact of novel IED prevention strategies.

查看原文本刊更多论文

美国侵袭性大肠杆菌病相关的经济和疾病负担

近年来，侵袭性大肠杆菌病（IED）的发病率在老龄化人群中有所增加，并且抗菌素耐药性也在上升。在这里，我们报告了一项对美国IED患者的比较、横断面、回顾性分析，以量化IED相关的医疗保健资源利用率（HCRU）、成本和对健康相关生活质量（HRQoL）的影响。方法：本研究纳入了2019年7月至2020年1月期间入组的Kaiser Permanente Northwest （KPNW）会员，年龄≥60岁。患者分为三组：第一组近期经历过IED发作（入组前≤3周）；第2组曾经历过IED发作（入组前13-18个月）；第三组无IED病史，有危险。数据收集自电子医院记录、患者调查和EuroQol 5维5级（EQ-5D-5L）问卷。根据个别随访调整平均费用。结果：1组（n = 289）、2组（n = 319）和3组（n = 340）患者特征基本一致。第1组、第2组和第3组分别有84%、44%和15%的患者住院。在1、2和3组中，每位患者（每30天随访）的平均直接费用分别为17,168美元、2530美元和1094美元。每名患者在IED发作后一年的平均总费用（组2）为35,034美元，而高危组3为16,163美元。近期IED患者的HRQoL较差，在病情最严重的当天，EQ-5D-5L效用指数平均值为0.25。在12个月的随访期间，从IED中恢复的患者的再住院率和平均抗生素处方数比有风险的患者高出约3倍。结论：这些数据证明了IED对HCRU、IED相关费用和HRQoL的短期和长期影响。需要进一步的研究来进一步评估新的IED预防策略的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Diseases and Therapy Medicine-Microbiology (medical)

CiteScore

8.60

自引率

1.90%

发文量

136

审稿时长

6 weeks

期刊介绍： Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.